Endocrine Abstracts

Background: Primary hyperparathyroidism (PHPT) reduces bone mineral density (BMD), leading to secondary osteoporosis. While parathyroidectomy has been reported to increase BMD, the efficacy of medical therapy for PHPT-induced osteoporosis after parathyroidectomy remains uncertain. Herein, we report two PHPT cases with osteoporosis, where romosozumab, an anti-sclerostin monoclonal antibody, increased BMDs after parathyroidectomy.Case 1: A 67-year-old woma...